Loading
Every dated change on the records linked to Advanced cutaneous squamous cell carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Cemiplimab for high-risk disease (C-POST, 2025).
Disease-free survival at 24 months 87.
A milestone in how this cancer is treated.
Metastatic or locally advanced cutaneous SCC not curable by surgery or radiation
No kidney rejection or graft loss in 12 kidney transplant recipients given cemiplimab after cross-taper to a mammalian target of rapamycin inhibitor with pulsed corticosteroids, with responses in 5 of 11 evaluable patients (46 per cent, 90 per cent confidence interval 22 to 73).
A milestone in how this cancer is treated.
Pathological complete response in 40 of 79 patients (51 per cent, 95 per cent confidence interval 39 to 62) and pathological major response in a further 13 per cent, with grade 3 or higher adverse events in 18 per cent.
A milestone in how this cancer is treated.
Advanced cutaneous squamous cell carcinoma
Objective response 47% in the metastatic group; 46% in the pooled analysis of 193 patients with 16% complete responses.
A milestone in how this cancer is treated.